Skip to main content

Table 6 Univariate and multivariate analysis of predictors of complication after caudate lobe ablation

From: Predictive factors of treatment outcomes after percutaneous ablation of hepatocellular carcinoma in the caudate lobe: a retrospective study

Factors

Univariate

Multivariate

P value

HR

95%CI

P value

Gender(M/F)

1.000

   

Age(≤60/>60y)

0.359

   

Tumor type (naive/recurrent)

0.410

   

Etiology (Hepatitis/others)

0.691

   

Type (Naïve/recurrent)

0.299

   

Surgery history of liver (Y/N)

1.000

   

Liver cirrhosis (Y/N)

0.113

   

ECOG performance status (0/1)

0.765

   

Child-Pugh (A/B)

0.104

   

BCLC stage of primary HCC (A/B)

0.453

   

AFP (≥400/< 400 μg/L)

0.861

   

PLT (≥100/< 100 × 109/L)

1.000

   

PT (≤14/> 14 s)

1.000

   

ALB (≤35/> 35 g/L)

1.000

   

ALT (≤40/> 40 IU/L)

0.164

   

TB (≤17.1/> 17.1 mol/L)

1.000

   

Tumor number (single/multiple)

1.000

   

Location (Paracaval portion/ Caudate process/ Spiegel’s lobe)

0.727

   

Tumor size (≤2 cm /> 2 cm)

0.691

   

Puncture approach (LA/ RA/ combination approach)

0.724

   

Treatment strategy

RFA/ EA/ RFA-EA

0.832

   

EA/RFA or RFA-EA

0.674

   

RFA or EA/RFA-EA

1.000

   

AM (≥ 5 mm / < 5 mm)

0.443

   
  1. HBV hepatitis B virus, HCV hepatitis C virus, ECOG East Coast Oncology Group, BCLC Barcelona Clinic Liver Cancer, AFP alpha-fetoprotein, PLT platelets, PT prothrombin time, ALB albumin, ALT alanine aminotransferase, TB total bilirubin, LA left lobe approach, RA right intercostal approach, EA ethanol ablation, RFA radiofrequency ablation, RFA-EA combination of RFA and EA, AM ablative margin